Physician profile
Upendra M Shah
NPI 1164492088
$2,084.63
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $874 · 2020: $335 · 2021: $732 · 2022: $21.36 · 2024: $123.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $123.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $122.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $523.52 | 2019-2021 | |
| Aspira Women'S Health INC | $385.42 | 2019-2021 | |
| Hologic Sales and Service, LLC | $277.91 | 2019-2021 | |
| Therapeuticsmd, INC. | $215.72 | 2019-2020 | |
| Organon LLC | $122.78 | 2024 | |
| Lupin INC. | $103.91 | 2019 | |
| Conmed Corporation | $85.65 | 2019 | |
| Covidien LP | $50.00 | 2020 | |
| Amag Pharmaceuticals, INC. | $48.41 | 2019-2020 | |
| Pfizer INC. | $47.93 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $46.99 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $32.90 | 2019-2020 | |
| Glaxosmithkline, LLC. | $31.54 | 2020-2021 | |
| Roche Diagnostics Corporation | $30.29 | 2019 | |
| Heron Therapeutics, INC. | $21.36 | 2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exeltis, USA INC. | $20.25 | 2021 | |
| Agile Therapeutics, INC. | $15.23 | 2021 | |
| Medicem INC. | $13.59 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $11.23 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Upendra Shah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.